ClinicalTrials.gg
Status unknownNCT03150602Updated May 12, 2017

A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

A Phase 4 interventional study of Pralatrexate in Peripheral T Cell Lymphoma and Progression, Disease, sponsored by Taiwan Mundipharma Pharmaceuticals Ltd.. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Taiwan Mundipharma Pharmaceuticals Ltd. (part of Mundipharma) · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2016, registered May 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral — none open to participants now, 1 under way, 1 of them phase 3. pralatrexate · Lymphoma, T-Cell, Peripheral.

Planned enrollment
10th of 11
22 · median 48
Started
2016
the only one that year
Phase 4
Only one
of the 11
Registered
10th of 11
by date
Lead sponsor
1 of 11
Taiwan Mundipharma Pharmaceuticals Ltd.

Among the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral, this one is the 10th largest by planned enrollment, is the only one that started in 2016, is the only one in phase 4, and was the 10th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

None of the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral is open now. The open studies under Lymphoma, T-Cell, Peripheral, anywhere →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral as a file.
02

Study summary

This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Read the detailed description

Peripheral T-cell lymphomas (PTCL) are a group of aggressive and diverse lymphoproliferative disorders. It is characterized by the presence of malignant mature T-cells or NK cells. There is as yet no consensus regarding standard frontline or relapsed/refractory therapy for PTCL.

A previous phase II study conducted in US showed durable responses of pralatrexate treatment in relapsed or refractory PTCL, irrespective of age, histological subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. This single-arm, multi-center study aims to evaluate the efficacy and safety of pralatrexate monotherapy in prior treatment failure PTCL patients who may undergo HSCT in case of CR or PR, or continue pralatrexate in case of CR, PR or SD.

Primary objective:

  • To evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Secondary objectives:

  • To determine the safety of pralatrexate in Asian PTCL patients by,

    • Incidence of adverse events (AEs) and serious adverse events (SAEs) emergent from the treatment
  • To evaluate the efficacy of pralatrexate in Asian PTCL patients after prior treatment failure by,

    • Overall survival (OS), progression-free-survival (PFS), complete response (CR) and partial response (PR) rate, and duration of CR and PR
    • Treatment duration with pralatrexate in the patients without hematopoietic stem cell transplant (HSCT) who achieve CR or PR
    • Percentage of patients who undergo HSCT
    • 1-year OS, 1-year PFS, and 1-year relapse rate after HSCT
    • 2-year OS, 2-year PFS, and 2-year relapse rate after HSCT
03

Conditions studied

  • Peripheral T Cell Lymphoma
  • Progression, Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 20 years of age, inclusive
  2. Patients with histologically/ confirmed PTCL using either: NCCN diagnosis criteria, the Revised European American Lymphoma (REAL), and World Health Organization (WHO) disease classification (PTCL histology/cytology subtypes diagnosed by site investigators, PTCL histology/cytology subtypes rechecked by study central pathology lab):

    1. At least 5 patients with Peripheral T-cell lymphoma, NOS
    2. At least 5 patients with Angioimmunoblastic T-cell lymphoma
    3. At least 5 patients with Extranodal NK/T-cell lymphoma, nasal type
    4. Enteropathy-type T-cell lymphoma
    5. Hepatosplenic T-cell lymphoma
    6. Subcutaneous panniculitis-like T-cell lymphoma
    7. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
  3. Patients with documented progressive disease (PD) failed after prior treatment

    1. Patients may not have received an experimental drug as their only prior therapy
    2. Patient has had at least 1 from initial diagnosis of PTCL or in the setting to confirm PTCL subtypes
    3. Patient has recovered from the toxic effects of prior therapy
  4. (ECOG) Performance Status ≤ 2.
  5. Adequate hematological, hepatic, and renal function as defined by: (ANC) ≥ 1000/µL, count ≥ 100,000/µL (and ≥ 50,000/µL for any following dose), total ≤ 1.5 mg/dL, (AST) and alanine aminotransferase (ALT) ≤ 2.5 X (ULN) (AST/ALT \< 5 X ULN if documented hepatic involvement with lymphoma), creatinine ≤ 1.5 mg/dL or a calculated ≥ 50 mL/min.
  6. Women of must agree to practice medically acceptable regimen from 30 days prior to study treatment initiation until at least 30 days after the last administration of pralatrexate and must have had a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are for at least 1 year (> 12 months since last menses) or were surgically sterilized do not require this test.
  7. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
  8. Patient has provided written (IC)

Exclusion criteria

Exclusion Criteria:

  1. Patient has following subtypes (histologically/ confirmed) of PTCL

    1. Anaplastic large cell lymphoma, ALK +/-
    2. Patient has: Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
    3. T-cell prolymphocytic leukemia (T-PLL)
    4. T-cell large granular lymphocytic leukemia
    5. Mycosis fungoides and transformed mycosis fungoides
    6. Sézary syndrome
    7. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
    8. Patient has: Extranodal NK/T-cell lymphoma, nasal type with local recurrence
  2. Active concurrent (except for non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.
  3. Congestive heart failure Class III/IV according to the 's Heart Failure guidelines.
  4. Patients with (HIV)-positive diagnosis and are receiving combination anti-retroviral therapy.
  5. Current or the history of or central nervous system (CNS) diseases
  6. Have undergone stem cell transplant
  7. less than 75 days from time of autologous stem cell transplant
  8. Patients with uncontrolled hypertension, active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment
  9. Had major surgery within 2 weeks of study entry
  10. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
  11. Receipt of within 7 days of study treatment, unless patient has been taking a stable dose of no more than 10 mg/day of prednisone for at least 1 month
  12. Use of any drug, biologic modifier, or device within 4 weeks prior to study treatment or planned use during the course of the study
  13. Previous exposure to pralatrexate
  14. Other conditions that investigators consider not suitable for study enrollment
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Pralatrexate treatment

    Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day

    Drug: Pralatrexate

Interventions

  • This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.

    Also known as: Folotyn

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) to pralatrexate treatment in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

    Time frame: Up to 35 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence of adverse events (AE) and serious adverse events (SAE) emergent from the treatment

    Time frame: Up to 40 weeks

  2. Overall survival

    Duration of overall survival (months)

    Time frame: Up to 5 years

  3. Progression-free survival

    Duration of PFS (months)

    Time frame: Up to 5 years

  4. Completion response rate

    The percentage of CR

    Time frame: Up to 5 years

  5. Partial response rate

    The percentage of PR

    Time frame: Up to 5 years

  6. Duration of CR and PR

    Duration of completion response and partial response (days)

    Time frame: Up to 5 years

  7. Treatment duration

    Treatment duration with pralatrexate in the patients without HSCT who achieve CR or PR

    Time frame: Up to 35 weeks

  8. Hematopoietic stem cell transplant (HSCT)

    Percentage of patients who undergo HSCT

    Time frame: Up to 5 years

  9. 1-year OS rate after HSCT

    1-year overall survival rate after conducting HSCT

    Time frame: Up to 1 year

  10. 1-year PFS rate after HSCT

    1-year progression-free survival rate after conducting HSCT

    Time frame: Up to 1 year

  11. 1-year relapse rate after HSCT

    1-year relapse rate after conducting HSCT

    Time frame: Up to 1 year

  12. 2-year OS rate after HSCT

    2-year overall survival rate after conducting HSCT

    Time frame: Up to 2 years

  13. 2-year PFS rate after HSCT

    2-year progression-free survival rate after conducting HSCT

    Time frame: Up to 2 years

  14. 2-year relapse rate after HSCT

    2-year relapse rate after conducting HSCT

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Ntional Taiwan University Hospital
    Taipei, 100, Taiwan
    Recruiting
08

References and documents

Publications

  • Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007 Jul;21(4):201-16. doi: 10.1016/j.blre.2007.03.001. Epub 2007 May 18. PubMed 17512649 ↗
  • Shustov A. Novel therapies for peripheral T-cell lymphomas. Ther Adv Hematol. 2013 Jun;4(3):173-87. doi: 10.1177/2040620713481980. PubMed 23730495 ↗
  • Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504. doi: 10.1182/blood-2008-01-134270. Epub 2008 Apr 2. PubMed 18385450 ↗
  • Society TLL, Peripheral T-Cell Lymphoma Facts, 2014.
  • Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003 Jun;44(6):1027-35. doi: 10.1080/1042819031000077124. PubMed 12854905 ↗
  • Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000 Sep;6(9):3493-8. Erratum In: Clin Cancer Res 2001 Apr;7(4):1102. PubMed 10999734 ↗
  • O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. PubMed 21245435 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2016 (actual). Primary completion is estimated for Dec 2020, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2017
First posted
May 12, 2017
StartActual
Aug 30, 2016
Primary completionEst.
Dec 31, 2020
CompletionEst.
Dec 31, 2020
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03150602
Responsible party
Sponsor
First posted
May 12, 2017
Start date
Aug 30, 2016
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
May 12, 2017

Study contacts

Bor-Sheng Ko, PhD
Contact
kevinkomd@gmail.com
886-23123456 ext. 63576
Brook Chung, MSc
Contact
brook.chung@mundipharma.com.tw
886-87297521
Bor-Sheng Ko, PhD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion